cretostimogene grenadenorepvec

Sponsor CG Oncology, INC. · listed as CGON

READOUT Phase 3 Confidence: medium Source: clinicaltrials

cretostimogene grenadenorepvec is a clinical-stage drug asset sponsored by CG Oncology, INC., listed as CGON. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 2026 (month precision, medium confidence), tied to trial NCT06111235. The asset is in Phase 3 and currently active not recruiting, studied in Non Muscle Invasive Bladder Cancer. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-11-30

As disclosedNov 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06111235

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorCG Oncology, Inc.

Listed asCGON

Condition(s)Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More CGON catalysts